---
schema_version: "secwatch.filing_event.v1"
accession: "0002019410-25-000011"
form_type: "8-K"
ticker: "CAI"
cik: "0002019410"
company_name: "Caris Life Sciences, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:55:56.080069+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caris Life Sciences Q2 2025 revenue $181.4M (+81% YoY); Adj. EBITDA positive $16.7M; FY rev guidance $675-685M

## Summary
- Total revenue $181.4M, up 81.3% YoY; gross margin 62.7% vs 37.5% a year ago.
- Net loss $71.8M includes $37.1M one-time IPO conversion expense; positive Adj. EBITDA $16.7M and positive free cash flow $5.9M.
- Clinical therapy selection volume 50,032 cases (+22% YoY); MI Profile volume +17.7%, Caris Assure volume +56.3%.
- FY2025 revenue guidance $675-685M (64-66% growth); clinical volume growth expected 19-21%.
- Recent IPO raised $519.5M net; cash and securities $724.9M at June 30, 2025.

## SEC filing metadata
- accession: 0002019410-25-000011
- form_type: 8-K
- ticker: CAI
- cik: 0002019410
- company_name: Caris Life Sciences, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2019410/000201941025000011/0002019410-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2019410/000201941025000011/cai-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002019410-25-000011
- JSON: https://secwatch.observer/filing/0002019410-25-000011.json
- Plain text: https://secwatch.observer/filing/0002019410-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.